Although the molecular mechanisms surrounding BET inhibitor action are still poorly understood, BET inhibitors are already undergoing clinical trials in a wide range of cancers (Andrieu et al., 2016, Fujisawa and Filippakopoulos, 2017). Here, DNER is linked to cancer.